Compare Stocks: PALI, HELP, SPTX, and TBPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HELP Cybin	$11.70 -1.8%	$11.75	$3.76 ▼ $15.15	$921.73M	0.53	1.68 million shs	1.41 million shs
PALI Palisade Bio	$1.44 +0.7%	$1.92	$1.32 ▼ $2.86	$250.95M	1.61	3.94 million shs	1.99 million shs
SPTX Seaport Therapeutics	$18.42 -2.8%	$22.67	$14.85 ▼ $28.38	$986.04M	N/A	302,281 shs	258,699 shs
TBPH Theravance Biopharma	$17.03	$16.99	$13.08 ▼ $21.03	$884.18M	0.25	680,323 shs	N/A

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HELP Cybin	-1.76%	-7.22%	-2.09%	+87.50%	+1,169,999,900.00%
PALI Palisade Bio	+0.70%	-0.69%	-27.64%	-31.43%	+9.92%
SPTX Seaport Therapeutics	-2.80%	-14.41%	-26.05%	-10.45%	+1,841,999,900.00%
TBPH Theravance Biopharma	0.00%	0.00%	-0.23%	+0.59%	+18.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HELP Cybin	$11.70 -1.8%	$11.75	$3.76 ▼ $15.15	$921.73M	0.53	1.68 million shs	1.41 million shs
PALI Palisade Bio	$1.44 +0.7%	$1.92	$1.32 ▼ $2.86	$250.95M	1.61	3.94 million shs	1.99 million shs
SPTX Seaport Therapeutics	$18.42 -2.8%	$22.67	$14.85 ▼ $28.38	$986.04M	N/A	302,281 shs	258,699 shs
TBPH Theravance Biopharma	$17.03	$16.99	$13.08 ▼ $21.03	$884.18M	0.25	680,323 shs	N/A

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HELP Cybin	-1.76%	-7.22%	-2.09%	+87.50%	+1,169,999,900.00%
PALI Palisade Bio	+0.70%	-0.69%	-27.64%	-31.43%	+9.92%
SPTX Seaport Therapeutics	-2.80%	-14.41%	-26.05%	-10.45%	+1,841,999,900.00%
TBPH Theravance Biopharma	0.00%	0.00%	-0.23%	+0.59%	+18.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HELP Cybin	3.00	Buy	$46.33	296.01% Upside
PALI Palisade Bio	3.00	Buy	$9.83	582.87% Upside
SPTX Seaport Therapeutics	2.50	Moderate Buy	$38.57	109.40% Upside
TBPH Theravance Biopharma	2.00	Hold	$19.40	13.92% Upside

Current Analyst Ratings Breakdown

Latest PALI, HELP, SPTX, and TBPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	SPTX Seaport Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
9/25/2026	SPTX Seaport Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$46.00
9/25/2026	SPTX Seaport Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$46.00
9/24/2026	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/23/2026	PALI Palisade Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
9/18/2026	HELP Cybin	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$35.00
9/10/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
9/7/2026	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/26/2026	SPTX Seaport Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$32.00
8/20/2026	HELP Cybin	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $62.00
8/20/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HELP Cybin	N/A	N/A	N/A	N/A	$4.49 per share	N/A
PALI Palisade Bio	$500K	501.90	N/A	N/A	$0.87 per share	1.66
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	$104.31M	8.48	N/A	N/A	$5.86 per share	2.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HELP Cybin	-$148M	-$3.02	N/A	N/A	N/A	N/A	-71.78%	-64.81%	N/A
PALI Palisade Bio	-$16.78M	-$0.48	N/A	N/A	N/A	N/A	-33.47%	-31.79%	11/9/2026 (Estimated)
SPTX Seaport Therapeutics	-$74.88M	-$12.12	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	$105.89M	$1.01	16.86	21.02	N/A	51.58%	-0.77%	-0.46%	11/10/2026 (Estimated)

Latest PALI, HELP, SPTX, and TBPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	HELP Cybin	-$0.80	-$0.91	-$0.11	-$0.91	N/A	N/A
8/10/2026	Q2 2026	PALI Palisade Bio	-$0.0522	-$0.05	+$0.0022	-$0.05	$0.50 million	$0.50 million
8/10/2026	Q2 2026	TBPH Theravance Biopharma	$0.0725	-$0.11	-$0.1825	-$0.11	$22.49 million	$20.73 million
8/3/2026	Q2 2026	SPTX Seaport Therapeutics	-$0.71	-$1.78	-$1.07	-$1.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HELP Cybin	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HELP Cybin	N/A	10.97	10.97
PALI Palisade Bio	N/A	24.26	24.26
SPTX Seaport Therapeutics	N/A	18.00	18.00
TBPH Theravance Biopharma	N/A	13.54	13.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HELP Cybin	17.94%
PALI Palisade Bio	11.79%
SPTX Seaport Therapeutics	N/A
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
HELP Cybin	15.00%
PALI Palisade Bio	0.07%
SPTX Seaport Therapeutics	N/A
TBPH Theravance Biopharma	7.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HELP Cybin	100	78.78 million	66.96 million	N/A
PALI Palisade Bio	14	174.27 million	174.15 million	Not Optionable
SPTX Seaport Therapeutics	58	53.53 million	N/A	N/A
TBPH Theravance Biopharma	110	51.92 million	47.95 million	Optionable

PALI, HELP, SPTX, and TBPH Headlines

Recent News About These Companies

Head to Head Contrast: Lifecore Biomedical (NASDAQ:LFCR) & Theravance Biopharma (NASDAQ:TBPH)

October 1 at 2:15 AM | americanbankingnews.com

Zymeworks completes $17 per share Theravance deal

September 28, 2026 | grafa.comG

Theravance Biopharma (NASDAQ:TBPH) Stock Rating Reaffirmed as "Neutral" by BTIG Research

September 26, 2026 | americanbankingnews.com

Theravance Biopharma (NASDAQ:TBPH) vs. Fortress Biotech (NASDAQ:FBIO) Head-To-Head Comparison

September 25, 2026 | americanbankingnews.com

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell Small Cap Completeness Index

September 24, 2026 | marketscreener.comM

Theravance Biopharma, Inc. annonce des changements au sein de son conseil d’administration, effectifs au 23 septembre 2026

September 24, 2026 | zonebourse.comZ

Theravance Biopharma, Inc. annonce la démission de Rick E Winningham de son poste de directeur général, effective le 23 septembre 2026

September 24, 2026 | zonebourse.comZ

Theravance Biopharma (NASDAQ:TBPH) Receives Neutral Rating from BTIG Research

September 24, 2026 | marketbeat.com

Zymeworks Inc. (NasdaqGS:ZYME) hat Theravance Biopharma, Inc. (NasdaqGM:TBPH) übernommen.

September 24, 2026 | de.marketscreener.comD

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P TMI Index

September 23, 2026 | marketscreener.comM

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P Global BMI Index

September 22, 2026 | marketscreener.comM

Theravance Biopharma (NASDAQ:TBPH) Sees Unusually-High Trading Volume - Still a Buy?

September 22, 2026 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of "Hold" by Analysts

September 22, 2026 | americanbankingnews.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Recommendation of "Hold" by Analysts

September 22, 2026 | marketbeat.com

Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow

September 18, 2026 | seekingalpha.com

Theravance Biopharma (NASDAQ:TBPH) SVP Sells 13,314 Shares

September 18, 2026 | insidertrades.com

Insider Selling: Theravance Biopharma (NASDAQ:TBPH) SVP Sells 13,314 Shares

September 17, 2026 | marketbeat.com

VIRGINIA RETIREMENT SYSTEMS ET Al Invests $1.07 Million in Theravance Biopharma, Inc. $TBPH

September 14, 2026 | marketbeat.com

Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?

September 9, 2026 | zacks.com

Theravance Biopharma (NASDAQ:TBPH) Downgraded by Zacks Research to "Hold"

September 9, 2026 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?

September 9, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PALI, HELP, SPTX, and TBPH Company Descriptions

Cybin NASDAQ:HELP

$11.70 -0.21 (-1.76%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$11.79 +0.09 (+0.76%)

As of 10/2/2026 07:56 PM Eastern

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Palisade Bio NASDAQ:PALI

$1.44 +0.01 (+0.70%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.44 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Seaport Therapeutics NASDAQ:SPTX

$18.42 -0.53 (-2.80%)

As of 10/2/2026 04:00 PM Eastern

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.

Theravance Biopharma NASDAQ:TBPH

$17.03 0.00 (0.00%)

As of 10/2/2026

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PALI, HELP, SPTX, and TBPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PALI, HELP, SPTX, and TBPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PALI, HELP, SPTX, and TBPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PALI, HELP, SPTX, and TBPH Company Descriptions

Cybin NASDAQ:HELP

Palisade Bio NASDAQ:PALI

Seaport Therapeutics NASDAQ:SPTX

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PALI, HELP, SPTX, and TBPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PALI, HELP, SPTX, and TBPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PALI, HELP, SPTX, and TBPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PALI, HELP, SPTX, and TBPH Company Descriptions

Cybin NASDAQ:HELP

Palisade Bio NASDAQ:PALI

Seaport Therapeutics NASDAQ:SPTX

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools